Safety of dupilumab in atopic patients during COVID-19 outbreak

J Dermatolog Treat. 2022 Feb;33(1):600-601. doi: 10.1080/09546634.2020.1771257. Epub 2020 Jun 19.

Authors

Maddalena Napolitano¹, Cataldo Patruno², Angelo Ruggiero³, Mariateresa Nocerino³, Gabriella Fabbrocini³

Affiliations

¹ Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
² Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
³ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 32419563
DOI: 10.1080/09546634.2020.1771257

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19*
Disease Outbreaks
Humans
SARS-CoV-2
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab